Alpa Laboratories Ltd (ALPA) is currently trading at 63.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Alpa Laboratories Limited is a pharmaceutical company established in 1988, specializing in the manufacture of pharmaceutical formulations across various dosage forms, including injectables, tablets, and creams. The company serves a broad market, including ethical, generic, over-the-counter drugs, and veterinary products, with a marked presence in both domestic and international markets. Alpa Laboratories holds a robust contract manufacturing portfolio, servicing renowned pharmaceutical companies like Cipla, Zydus Cadila, and international markets in countries such as the Philippines and Nigeria. The company underwent significant expansions, such as the establishment of a new manufacturing unit in 1999 and the operational start of their oral dosage facility in 2012. In 2007, Alpa Laboratories went public, listing on major Indian stock exchanges and further expanding its market reach and capital base.

Over the past 52 weeks, Alpa Laboratories Ltd has traded between a low of ₹55.10 and a high of ₹124.88. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Alpa Laboratories Ltd has a market capitalization of approximately 128.83. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Alpa Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 11.36 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 128.83 Cr, Alpa Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Alpa Laboratories Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Alpa Laboratories Ltd is 11.36. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.